Entering text into the input field will update the search result below

Mustang Bio shares triple in price on new 'bubble boy' therapy data

Apr. 17, 2019 5:25 PM ETBy: Jason Aycock, SA News Editor19 Comments
  • Mustang Bio (MBIO) has tripled up, jumping 199% after hours, after releasing new data from a phase 1/2 clinical trial.
  • The trial is of a lentiviral gene therapy for treating newly diagnosed infants with X-linked Severe Combined Immunodeficiency -- popularly known as bubble boy disease.
  • Mustang will develop the therapy in conjunction with St. Jude Children's Research Hospital as MB-107.
  • Ten infants were treated with the therapy and the data covers eight who were followed for a median of 16.4 months: Bone marrow harvest, busulfan conditioning and cell infusion were well tolerated; in seven cases, normalization of CD3+, CD4+ and CD4+ naïve T-cell and natural killer cell numbers came in 3-4 months; all patients cleared previous infections; and seven of the eight developed normal IgM levels.
  • Fortress Biotech (FBIO), which owns a 38% stake in Mustang Bio, is up 91.8% after hours.

Recommended For You